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Abstract
Butadiene (BD) metabolism shows gender, species and concentration dependency, making the
extrapolation of animal results to humans complex. BD is metabolized mainly by cytochrome P450
2E1 to three epoxides, 1,2-epoxy-3-butene (EB), 1,2;3,4-diepoxybutane (DEB) and 1,2-epoxy-
butanediol (EB-diol). For accurate risk assessment it is important to elucidate species differences in
the internal formation of the individual epoxides in order to assign the relative risks associated with
their different mutagenic potencies. Analysis of N-terminal globin adducts is a common approach
for monitoring the internal formation of BD derived epoxides. Our long term strategy is to develop
an LC–MS/MS method for simultaneous detection of all three BD hemoglobin adducts. This
approach is modeled after the recently reported immunoaffinity LC–MS/MS method for the cyclic
N,N-(2,3-dihydroxy-1,4-butadyil)-valine (pyr-Val, derived from DEB). We report herein the analysis
of the EB-derived 2-hydroxyl-3-butenyl-valine peptide (HB-Val). The procedure utilizes trypsin
hydrolysis of globin and immunoaffinity (IA) purification of alkylated heptapeptides. Quantitation
is based on LC–MS/MS monitoring of the transition from the singly charged molecular ion of HB-
Val (1–7) to the a1 fragment. Human HB-Val (1–11) was synthesized and used for antibody
production. As internal standard, the labeled rat-[13C515N]-Val (1–11) was prepared through direct
alkylation of the corresponding peptide with EB. Standards were characterized and quantified by
LC–MS/MS and LC–UV. The method was validated with different amounts of human HB-Val
standard. The recovery was >75% and coefficient of variation <25%. The LOQ was set to 100 fmol/
injection. For a proof of principal experiment, globin samples from male and female rats exposed to
1000 ppm BD for 90 days were analyzed. The amounts of HB-Val present were 268.2 ± 56 and 350
± 70 pmol/g (mean ± S.D.) for males and females, respectively. No HB-Val was detected in controls.
These data are much lower compared to previously reported values measured by GC–MS/MS. The
difference may be due higher specificity of the LC–MS/MS method to the N-terminal peptide from
the α-chain versus derivatization of both α- and β-chain by Edman degradation, and possible
instability of HB-Val adducts during long term storage (about 10 years) between the analyses. These
differences will be resolved by examining recently collected samples, using the same internal
standard for parallel analysis by GC–MS/MS and LC–MS/MS. Based on our experience with pyr-
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1,3-Butadiene (BD) is an important industrial chemical used in the production of synthetic
rubber that is also found in gasoline, cigarette smoke, and auto exhaust [1]. Epidemiologic
studies have shown an increased incidence of leukemia in workers exposed to BD in synthetic
rubber production [2] and an increase in lymphohematopoietic cancers in BD production
workers [3]. The NTP and US EPA have categorized BD as carcinogenic to humans by
inhalation, while IARC classifies BD as a probable human carcinogen [4–6]. It has clearly been
demonstrated that BD is a multi-species, multi-site carcinogen in rodents, with mice being a
much more sensitive species than rats [4,7–11].
BD metabolism is gender, species and concentration dependent. This makes the extrapolation
of animal results to humans complex. The electrophilic metabolites of BD are 1,2-epoxy-3-
butene (EB), 1,2;3,4-diepoxybutane (DEB), and 1,2-epoxy-3,4-butanediol (EB-diol) (Scheme
1). They exhibit significantly different mutagenicity, with DEB being 100- and 200-fold more
mutagenic than EB and EB-diol, respectively. Therefore it is important to elucidate the internal
formation of the individual epoxides in order to assign their relative importance in mutagenesis
and carcinogenesis. The formation of protein adducts as surrogate markers for exposure has
been widely accepted. Methods have been established to monitor exposure to occupational
toxins, carcinogens and to tobacco specific carcinogens [12]. Hemoglobin (Hb) and serum
albumin adducts are used most widely, because they have the advantages of being readily
accessible, accumulate over the life time of the protein (60 days for rat erythrocytes) and, unlike
DNA adducts, are not repaired. In addition to exposure assessments, the use of protein adducts
was recently reported for studying different metabolic pathways in vivo [13], an important issue
for BD.
The protein adducts formed by EB, DEB and EB-diol are 2-hydroxyl-3-butenyl-valine (HB-
Val), N,N-(2,3-dihydroxy-1,4-butadyil)-valine (pyr-Val) and 2,3,4-trihydroxy butyl-valine
(THB-Val), respectively. These N-terminal valine adducts have been previously used as
biomarkers for the internal formation of the corresponding epoxides. Up to now, both HB-Val
and THB-Val adducts in rodents and humans only had been measured by GC–MS/MS, a
procedure based on the modified Edman degradation method of Törnqvist et al. [14]. A novel
LC–MS/MS method for analysis of pyr-Val was developed [15–17] and substantially improved
in the matter of sample purification by immunoaffinity chromatography (IA) and detection
sensitivity by capillary LC–ESI–MS/MS [13]. This allowed the measurement of the cyclic
adduct, pyr-Val, in a wide range of BD exposed samples from mice and rats, ranging from
concentrations as low as 1 ppm BD [18] to 1250 ppm BD. Here we report the development of
a similar method for the analysis of the EB specific HB-Val adduct in rats, as an incremental
step to our overall goal to develop a method for simultaneous analysis of all three BD-derived
N-terminal valine adducts by LC–MS/MS.
2. Materials and methods
Materials. Trypsin (biotin-agarose, from bovine pancreas) was purchased from Sigma–Aldrich
(St. Louis, MO). All reagents and solvents were ACS grade or higher. Centricon 3 filters were
obtained from Amicon Inc. (Beverly, MA) and Microspin filter tubes (regenerated cellulose,
0.2 um) were from Alltech Associates Inc. (Deerfield, IL). Polyclonal antibodies against HB-
Val (1–11) were raised by Anaspec (San Jose, CA) using peptides synthesized as described
below.
2.1. Synthesis of standard peptides
The N-terminal α-chain peptide for human HB-VLSPADKTNVC (human HB-Val (1–11)
standard) was synthesized based on the procedure described previously [19] and used for
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antibody production (see below). The stable isotope-labeled rat internal standard peptide (HB-
[13C515N]VLSADDKTNIK peptide) was synthesized for accurate quantitation, by direct
alkylation of the non-adducted [13C515N]-labeled rat (1–11) peptide with EB at molar ratio of
1:25, in water, pH 8.0, at 37°C for 42 h according to Fred et al. [15]. The corresponding HB-
Val (1–7) peptides were prepared from (1–11) peptides by trypsin hydrolysis as described
below. For the analysis of the rat samples 12 pmol internal standard was added prior to trypsin
hydrolysis.
2.2. Immunoaffinity chromatography
Polyclonal antibodies were raised against the human HB-Val (1–11) peptide, in which the C-
terminal lysine was substituted by cysteine to allow antibody production as described [13].
Immunoaffinity columns were prepared essentially according to Ham et al. [20].
2.3. Animals and exposures
Globin samples were available from male and female Sprague Dawley rats, 22 days of age,
exposed to 1000 ppm BD for 90 days at the Haskell Laboatory for Toxicology and Industrial
Medicine at DuPont (Newark, DE) [21]. All animals were sacrificed within 2 h post-exposure
by exsanguination under CO2 anesthesia. Blood samples were collected by cardiac puncture.
Red blood cells were isolated, washed twice with 0.9% saline, and stored at −80°C.
2.4. Globin isolation and trypsin hydrolysis
Globin was isolated according the protocol of Mowrer et al. [22] and processed as described
elsewhere [13]. Briefly, globin (about 20 mg) was dissolved in 0.1 M NH4HCO3, pH 8.0,
containing 12 pmol rat HB-Val internal standard and was digested with trypsin–biotin–agarose
enzyme suspension at 37°C for 20 h (shaking). The resulting peptide mixture was passed
through Centricon 3 filters and the HB-Val peptides were isolated by anti-HB-Val IA
chromatography. HB-Val (1–7) peptides were eluted in 5% formic acid, filtered through
Microspin (2 µm) columns and stored at −20°C until analyzed by UPLC–MS/MS.
2.5. Quantitative analysis of HB-Val adduct
The quantitative analysis of the HB-Val (1–7) peptides by LC–ESI–MS/MS was performed
with an UPLC (Waters, Milford, MS) coupled to a TSQ-Quantum triple quad mass analyzer
(ThermoFinnigan, San Jose, CA). A 1.0 mm × 100 mm UPLC™ BEH C18, 1.7 µm column
was operated with a linear gradient of 5% methanol–15 mM ammonium formate, pH 2.7, for
0.3 min then to 95% methanol–15 mM ammonium formate, pH 2.7, in 1 min, at a flow rate of
75 µl/min. The HB-Val retention times were determined with HB-(1–7) peptide standards. The
peptides were detected in single reaction monitoring (SRM) mode, monitoring the transition
of the singly charged ions to the a1-fragments (m/z 799 → 142, 817 → 142 and 823 → 147 for
human analyte, rat analyte and rat internal standard, respectively). The MS conditions were as
follows: spray voltage 2200 V, heated capillary temperature 350°C. The immunoaffinity
purified samples were reconstituted in 20 µl of water and 1 µl injected.
3. Results and discussion
The analysis of HB-Val and THB-Val by modified Edman degradation and subsequent analysis
by GC–MS/MS revealed important insights into species and exposure concentration
differences in BD metabolism. These previous studies highlighted the need for determination
of pyr-Val, which has been demonstrated recently by a peptide-LC–MS/MS approach [13], to
understand the role of the different epoxides in mutagenesis and carcinogenesis following
exposure to BD. The later methodology is less time consuming, more precise, highly specific
to alkylations of the N-terminus and to the analysis of other and possible multiple alkylations,
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simultaneously. The goal of this report was to establish a peptide method for the detection of
HB-Val, as an initial step towards a method for the simultaneous analysis of several BD derived
N-terminal adducts.
The strategy of the method presented herein is based on trypsin digestion and isolation of the
alkylated N-terminal heptapeptide by IA chromatography prior to quantitation by LC–MS/MS.
Therefore, the human HB-Val (1–11) was synthesized and used to raise polyclonal anti-HB-
Val antibodies. A fraction of HB-Val (1–11) was converted to HB-Val (1–7) by trypsin
hydrolysis and utilized for instrument optimatization. In addition, for accurate quantitation,
stable isotope labeled rat HB-[13C515N]Val (1–11) was prepared as internal standard by
reaction of EB with [13C515N]-valine labeled (1–11) peptide. The (1–7 and 1–11) standards
and internal standards were characterized by tandem mass spectrometry sequencing (Fig. 1)
using an LCQ-Deca ion trap mass analyzer (ThermoFinnigan, San Jose, CA) and the accurate
mass for the internal standard peptide was 823.44458 (expected 823.44398) as determined on
an 12-T FT-MS. The concentration of the human analyte standard used for MS-tuning,
optimization and method validation was determined by weight, and the amount of HB-Val in
the internal standard mixture was quantitated by UPLC–MS/MS versus the human HB-Val
(1–7), and by LC–UV versus the corresponding non-alkylated rat peptide according to [15].
The values obtained by both methods for rat HB-Val (1–7) internal standard were 240 and 200
pmol/µl, respectively (220 ± 20 mean pmol/µl).
Antibodies raised against the human peptide were used to produce IA columns for sample
purification, because our long term goal is to study BD metabolism in exposed humans. Control
globin was spiked with different amounts of analyte and internal standard peptides to determine
assay recovery and reproducibility (data not shown). Similar to our previous experience with
pyr-Val, IA columns prepared with serum from the second bleeding (8 weeks post
immunization) had better recovery compared to columns prepared with serum from the first
bleeding (75% versus 15%), based on amounts of internal standard loaded initially and
detected. The results also demonstrated that the polyclonal antibodies raised against the human
HB-Val (1–11) had equal affinity to the rat HB-Val (1–7).
Before the measurement of in vivo samples, the precision and accuracy of the method were
tested, as well as the recovery on the IA columns. The coefficient of variation (CV) was <25%
and the recovery was >75%. For instrument calibration and demonstration of linearity, a
calibration curve ranging from 50 to 500 fmol/µl was generated using the human HB-Val (1–
7) standard and rat [13C515N]HB-Val (1–7) internal standard (Fig. 2). From these calibration
solutions the LOQ was set to 100 fmol on column. Signal to noise ratio was determined within
the peaks and signals had to have a minimum of 14 points over the peak to be considered
detected. For the in vivo measurements, ∼20 mg of globin from rats exposed by inhalation to
0 (three females) or 1000 ppm BD (six males and six females) for 90 days were analyzed for
HB-Val. A representative chromatogram from a male rat (22 mg globin used) is shown in Fig.
3. The values found were 268 ± 56 and 350 ± 70 pmol/g globin for males and females,
respectively. This difference, however, was not statistically significant according to the t-test.
Female rats formed 1.3-fold more HB-Val compared to males (Fig. 4), a ratio that is close to
1.58 reported previously [23].
The amounts detected in the present study were about 24-fold lower compared to the analysis
of the same samples previously by GC–MS/MS [23]. To exclude the possibility that the
antibody used may have been raised against the minor C-2 regioisomer of HB-Val, the human
(1–11) standard used for antibody production was further characterized by HSQC- and HMBC-
NMR in D2O. These analyses confirmed the presence of only the C-1 regioisomer HB-Val
(data not shown). To explore the possible cause of the different results, we are analyzing
recently collected globin samples by LC–MS/MS and GC–MS/MS in parallel, using the
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internal standard from the peptide method. This experiment will show whether the differences
were caused by the methods or due to sample handling or storage (different methods conducted
more than 10 years apart). At this time the reasons for the difference are unknown and could
be due to: (1) the use of [2H6]-EB alkylated globin as internal standard for GC–MS/MS, which
meanwhile has been shown to be unstable, versus a newly synthesized internal standard peptide
for LC–MS/MS, (2) higher specificity of the new assay to the N-terminal peptide from the
globin α-chain only, with no quantitation of the β-chain, and (3) possible degradation of HB-
Val during the storage period (over 10 years) between the analyses.
In addition to the formation of N-terminal valine adducts, it has been reported that EB and
DEB also alkylate lysine, histidine, serine and methionine residues in the hemoglobin α- and
β-chain [24–27]. It has to be emphasized that these in vitro studies were performed to
qualitatively identify possible binding sites and were carried out at high molar ratios of EB (or
DEB) to protein, far different from the exposures encountered in vivo. While these residues
may be more reactive, the analysis of alkylation at one site has the advantage that no corrections
have to be made for accessibility and affinity of species specific individual residues towards
the different BD derived epoxides.
In conclusion, a new method for quantitation of EB derived HB-Val adduct has been
established. The data presented demonstrate excellent reproducibility with a CV <25% per
group (n = 5) and suitability for studying the internal formation of EB in vivo. The data are
qualitatively in agreement with previous analyses by GC–MS/MS, however the values are
about 24-fold lower. Further validation is underway to determine the source of this difference
and standardize the procedure so that comparable data are obtained with GC–MS/MS and LC–
MS/MS. Future focus will be to extend this technology by preparing IA columns that contain
multiple antibodies to allow analysis of HB-Val, pyr-Val and THB-Val simultaneously.
Abbreviations
BD, 1,3-butadiene; BD-diol, 3-butene-1,2-diol; CV, coefficient of variation; DEB, 1,2 ;3,4-
diepoxybutane; EB, 1,2-epoxy-3-butene; EB-diol, 1,2-epoxy-3,4-butanediol; EH, Epoxide
hydrolase; HB-Val, 2-hydroxy-3-butenyl-valine; pyr-Val, N,N-(2,3-dihydroxy-1,4-butadiyl)
valine; THB-Val, 2,3,4-trihydroxybutyl-valine.
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Characterization of rat [13C515N]HB-Val (1–11) and (1–7) internal standard peptide. (A) Full
scan (m/z 100–1500) of rat [13C515N]HB-Val (1–11) and (B) MS/MS spectrum of rat
[13C515N]HB-Val (1–7)
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Calibration curve for HB-Val.
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Ion-chromatogram of HB-Val peptide from a male rat exposed to 1000 ppm BD for 90 days.
Shown are the transitions of the analyte (m/z 817 → 142) and internal standard peptide (m/z
823 → 147).
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Comparison of HB-Val in male and female rats exposed to 1000 ppm BD for 90 days (mean
± S.D., n = 6).
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BD metabolism and formation of globin adducts.
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